DESCRIBE <http://purl.uniprot.org/SHA-384/DF68D38A7F2453DD74211C8A9A30BF69BF317AAC6A1E43DA7E2D937A5101651C0B10558EA2E433160C270E08D31B6004>

Subject	Predicate	Object
http://purl.uniprot.org/SHA-384/DF68D38A7F2453DD74211C8A9A30BF69BF317AAC6A1E43DA7E2D937A5101651C0B10558EA2E433160C270E08D31B6004	http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/DF68D38A7F2453DD74211C8A9A30BF69BF317AAC6A1E43DA7E2D937A5101651C0B10558EA2E433160C270E08D31B6004	http://www.w3.org/2000/01/rdf-schema#comment	"The ZBTB48 (TZAP) mutation (c.1272 G > A L424L) was found in 7.8% of128 breast cancer (BC) patients and was associated with the N0 stage. BCs with the TZAP mutation had longer telomeres than those without this mutation. Survival analysis showed that the TZAP mutation resulted in poorer overall survival."xsd:string
http://purl.uniprot.org/uniprot/#_C29537B40659922B77D5BF1A8918620710681152215A49FB647FEA4D97C668A8A5C7CA3A213FB32E4BCDA530979F77E3	http://www.w3.org/1999/02/22-rdf-syntax-ns#subject	http://purl.uniprot.org/SHA-384/DF68D38A7F2453DD74211C8A9A30BF69BF317AAC6A1E43DA7E2D937A5101651C0B10558EA2E433160C270E08D31B6004
http://purl.uniprot.org/uniprot/P10074	http://purl.uniprot.org/core/mappedAnnotation	http://purl.uniprot.org/SHA-384/DF68D38A7F2453DD74211C8A9A30BF69BF317AAC6A1E43DA7E2D937A5101651C0B10558EA2E433160C270E08D31B6004
http://purl.uniprot.org/uniprot/#_P10074-mappedCitation-31752241	http://purl.uniprot.org/core/mappedAnnotation	http://purl.uniprot.org/SHA-384/DF68D38A7F2453DD74211C8A9A30BF69BF317AAC6A1E43DA7E2D937A5101651C0B10558EA2E433160C270E08D31B6004